Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Interactions with a "Humanized" Mesenchymal Bone Marrow Stromal Niche In Vivo Modify the Patterns of Essential Genes for Myeloma Cells: Therapeutic Implications

Ryosuke Shirasaki, MD PhD, Sondra L. Downey-Kopyscinski, PhD, Ricardo De Matos Simoes, PhD, Olga Dashevsky, Sara Gandolfi, MD, Megan Bariteau, BSc, Aviad Tsherniak, PhD, Francisca Vazquez, PhD, Maria Themeli, MD PhD, Jonathan D. Licht, MD, Larry H. Boise, PhD, Richard W.J. Groen, PhD, Constantine S. Mitsiades, MD PhD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-143151

Published: 2020

Journal Articles

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Blood (2019) 134 (Supplement_1): 318.

https://doi.org/10.1182/blood-2019-130549

Published: 2019

Journal Articles

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Lisa C. Holthof, MSc, Hilma J. Van Der Horst, MSc, Renée Poels, Jort T. van der Schans, MSc, Anne T. Gelderloos, MSc, Fengzhi Li, Henk Lokhorst, MD PhD, Sonja Zweegman, MD PhD, Maria Themeli, MD PhD, Niels W. C. J. Van De Donk, Richard W.J. Groen, PhD, Tuna Mutis, MD PhD

Blood (2019) 134 (Supplement_1): 137.

https://doi.org/10.1182/blood-2019-125818

Published: 2019

Journal Articles

Establishing Human Niche Xenograft Models for Myeloid and Lymphoid Leukemia Driven By MLL-AF9

Marco Carretta, MSc, Jennifer Jaques, Bauke de Boer, MSc, Huipin Yuan, PhD, Anton C. Martens, PhD, Edo Vellenga, MDPhD, Richard W.J. Groen, PhD, Jan Jacob Schuringa, PhD

Blood (2014) 124 (21): 4781.

https://doi.org/10.1182/blood.V124.21.4781.4781

Published: 2014

Journal Articles

Evaluation of Extrinsic and Intrinsic Cues Involved in BCR-ABL-Induced Leukemogenesis

Pallavi Suhas Sontakke, MSC, Richard W.J. Groen, PhD, Katarzyna Koczula, MSC, Jennifer Jaques, Huipin Yuan, PhD, Ulrich Günther, PhD, Anton C. Martens, PhD, Edo Vellenga, MD PhD, Jan J. Schuringa, PhD

Blood (2014) 124 (21): 515.

https://doi.org/10.1182/blood.V124.21.515.515

Published: 2014

Journal Articles

Temporal Dynamics of Tumor-Microenvironment Interaction and Treatment Responses Revealed through Time-Lapse Compartment-Specific Bioluminescence Imaging: Translational implications

Eugen Dhimolea, PhD, Emily King, Efstathios Kastritis, MD, Douglas W. McMillin, PhD, Jake E. Delmore, B.Sc., Joseph M. Negri, B.Sc., Hannah M. Jacobs, B.Sc., Catriona A. Hayes, MD, Michal Sheffer, PhD, Yiguo Hu, PhD, Subhashis Sarkar, PhD, Richard W.J. Groen, PhD, Megan A. Bariteau, B.Sc., Blake T. Aftab, PhD, Constantine S. Mitsiades, MD PhD

Blood (2014) 124 (21): 276.

https://doi.org/10.1182/blood.V124.21.276.276

Published: 2014

Journal Articles

Genome-Scale Crispr-Cas9 Knockout Studies Reveal Mutifactorial and Functionally Overlapping Mechanisms of Myeloma Cell Resistance to Proteasome Inhibition

Michal Sheffer, PhD, Yiguo Hu, PhD, Ophir Shalem, PhD, Neville Sanjana, PhD, Eugen Dhimolea, PhD, Subhashis Sarkar, PhD, Megan A. Bariteau, B.Sc., Blake T. Aftab, PhD, Richard W.J. Groen, PhD, Feng Zhang, PhD, Constantine S. Mitsiades, MD PhD

Blood (2014) 124 (21): 273.

https://doi.org/10.1182/blood.V124.21.273.273

Published: 2014

Journal Articles

Modulation of CD38 Expression Levels on Multiple Myeloma Tumor Cells By All- Trans Retinoic Acid Improves the Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab

Inger S. Nijhof, MD, Henk M. Lokhorst, MDPhD, Berris van Kessel, Richard W.J. Groen, PhD, Anton C. Martens, PhD, Parul Doshi, PhD, Saskia K. Klein, MDPhD, Tuna Mutis, MDPhD, Kate Sasser, Niels W.C.J. van de Donk, MDPhD

Blood (2014) 124 (21): 2096.

https://doi.org/10.1182/blood.V124.21.2096.2096

Published: 2014

Journal Articles

Disregulated Osteogenesis By Mesenchymal Stromal Cells (MSC) After In Vivo Exposure To Multiple Myeloma: Studies In a Novel Humanized Mouse Model For Bone Remodelling In Myeloma

Richard W.J. Groen, PhD, Willy A. Noort, PhD, Jessica Sigmans, Aniek van Stralen, Linda Aalders, Reinier Raymakers, MD, PhD, Huipin Yuan, PhD, Constantine S. Mitsiades, MD, PhD, Anton Martens, PhD

Blood (2013) 122 (21): 1906.

https://doi.org/10.1182/blood.V122.21.1906.1906

Published: 2013

Journal Articles

Cell Non-Autonomous Modulation Of Tumor Cell Responses To Pharmacological Inhibition Of The Proteasome

Eugen Dhimolea, PhD, Richard W.J. Groen, PhD, Catriona A. Hayes, MD, Jana Jakubikova, PhD, Bariteau Megan, Jake E. Delmore, Hannah M. Jacobs, Julio-Cesar Marin, Gregory Della Penna, Douglas W. McMillin, PhD, Ana Acuna, Panisinee Lawasut, MD, Nancy Kohl, PhD, Constantine S. Mitsiades, MD, PhD

Blood (2013) 122 (21): 4454.

https://doi.org/10.1182/blood.V122.21.4454.4454

Published: 2013

Journal Articles

Nanoparticle Arsenic Compound Realgar Effectively Targets Myeloma Stem-Like Side Population

Jana Jakubikova, PhD, Teru Hideshima, MD, PhD, Richard W.J. Groen, PhD, Danka Cholujova, PhD, Zdenka Bujnakova, PhD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Constantine S. Mitsiades, MD, PhD, Peter Balaz, PhD, Jan Sedlak, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 4455.

https://doi.org/10.1182/blood.V122.21.4455.4455

Published: 2013

Journal Articles

Myeloma Patient-Derived Mesenchymal Stem Cells Grown In 3-D Culture Induce Primary Myeloma Cell Proliferation and Resistance To Therapy

Jana Jakubikova, PhD, Richard W.J. Groen, PhD, Teru Hideshima, MD, PhD, Danka Cholujova, PhD, Jan Sedlak, PhD, Constantine S. Mitsiades, MD, PhD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 1912.

https://doi.org/10.1182/blood.V122.21.1912.1912

Published: 2013

Journal Articles

Mouse Versus Human Extrinsic Cues Dictate Transformation Potential In BCR-ABL/BMI1-Induced Leukemia In Humanized Xenograft Models

Pallavi Sontakke, Richard W.J. Groen, PhD, Jennifer Jaques, Huipin Yuan, PhD, Anton Martens, PhD, Edo Vellenga, MD, PhD, Jan Jacob Schuringa, PhD

Blood (2013) 122 (21): 515.

https://doi.org/10.1182/blood.V122.21.515.515

Published: 2013

Journal Articles

CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients

Inger S. Nijhof, MD, Willy A. Noort, PhD, Jeroen Lammerts van Bueren, PhD, Berris van Kessel, Joost M. Bakker, PhD, Paul W.H.I. Parren, PhD, Richard W.J. Groen, PhD, Niels W.C.J. van de Donk, MD, PhD, Henk Lokhorst, Tuna Mutis, MD, PhD, Anton Martens, PhD

Blood (2013) 122 (21): 277.

https://doi.org/10.1182/blood.V122.21.277.277

Published: 2013

Journal Articles

Daratumumab, a Novel Human CD38 Monoclonal Antibody for Treatment of Multiple Myeloma, Prevents Intra-Medullary Spreading of Patient Derived Multiple Myeloma Cells Growing in a Humanized Mouse Model

Willy A Noort, PhD, Richard W.J. Groen, PhD, Reinier Raymakers, MD, PhD, Linda Aalders, Joost de Bruijn, PhD, Huipin Yuan, PhD, Jeroen Lammerts van Bueren, PhD, Paul W.H.I. Parren, PhD, Henk Lokhorst, MD, Tuna Mutis, MD PhD, Anton C.M. Martens, PhD

Blood (2012) 120 (21): 1834.

https://doi.org/10.1182/blood.V120.21.1834.1834

Published: 2012

Journal Articles

Tumor Cell-Dependent Differences in Stroma-Induced Changes to Bortezomib Sensitivity.

Eugen Dhimolea, PhD, Jana Jakubikova, PhD, Richard W.J. Groen, PhD, Jake E. Delmore, Hannah M. Jacobs, Douglas W. McMilllin, Ana Acuña-Villaorduña, MD, Catriona A. Hayes, MD, Panisinee Lawasut, MD, Constantine S. Mitsiades, MD, PhD

Blood (2012) 120 (21): 2468.

https://doi.org/10.1182/blood.V120.21.2468.2468

Published: 2012

Journal Articles

Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma

Jana Jakubikova, PhD, Richard W.J. Groen, PhD, Sophia Adamia, PhD, Teru Hideshima, MD, PhD, Danka Cholujova, PhD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 1812.

https://doi.org/10.1182/blood.V120.21.1812.1812

Published: 2012

Journal Articles

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model

Willy A Noort, PhD, Richard W.J. Groen, PhD, Reinier Raymakers, MD, PhD, Linda Aalders, Frans M Hofhuis, Berris Van Kessel, Jeroen F Van Velzen, Joost de Bruijn, PhD, Huipin Yuan, PhD, Jeroen Lammerts van Bueren, PhD, Andries C Bloem, PhD, Paul W.H.I. Parren, PhD, Henk Lokhorst, MD, Tuna Mutis, MD PhD, Anton C.M. Martens, PhD

Blood (2012) 120 (21): 940.

https://doi.org/10.1182/blood.V120.21.940.940

Published: 2012

Journal Articles

Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents

Catriona A. Hayes, MD, Paul Dowling, PhD, Richard W.J. Groen, PhD, Douglas W. McMillin, PhD, Jake E. Delmore, Hannah M. Jacobs, Niels W.C.J. van de Donk, MD, PhD, Eugen Dhimolea, PhD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Martin Clynes, PhD, Peter O'Gorman, M.D., Constantine S. Mitsiades, MD, PhD

Blood (2012) 120 (21): 3995.

https://doi.org/10.1182/blood.V120.21.3995.3995

Published: 2012

Journal Articles

Phagocytosis Is A Mechanism of Action for Daratumumab

Marije B. Overdijk, PhD student, Sandra Verploegen, PhD, Bögels Marijn, PhD student, Marjolein van Egmond, Prof., Richard W.J. Groen, PhD, Anton C.M. Martens, PhD, Jeroen Lammerts van Bueren, PhD, Wim Bleeker, PhD, Paul W.H.I. Parren, PhD

Blood (2012) 120 (21): 4054.

https://doi.org/10.1182/blood.V120.21.4054.4054

Published: 2012

NARROW

Interactions with a "Humanized" Mesenchymal Bone Marrow Stromal Niche In Vivo Modify the Patterns of Essential Genes for Myeloma Cells: Therapeutic Implications

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Establishing Human Niche Xenograft Models for Myeloid and Lymphoid Leukemia Driven By MLL-AF9

Evaluation of Extrinsic and Intrinsic Cues Involved in BCR-ABL-Induced Leukemogenesis

Temporal Dynamics of Tumor-Microenvironment Interaction and Treatment Responses Revealed through Time-Lapse Compartment-Specific Bioluminescence Imaging: Translational implications

Genome-Scale Crispr-Cas9 Knockout Studies Reveal Mutifactorial and Functionally Overlapping Mechanisms of Myeloma Cell Resistance to Proteasome Inhibition

Modulation of CD38 Expression Levels on Multiple Myeloma Tumor Cells By All- Trans Retinoic Acid Improves the Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab

Disregulated Osteogenesis By Mesenchymal Stromal Cells (MSC) After In Vivo Exposure To Multiple Myeloma: Studies In a Novel Humanized Mouse Model For Bone Remodelling In Myeloma

Cell Non-Autonomous Modulation Of Tumor Cell Responses To Pharmacological Inhibition Of The Proteasome

Nanoparticle Arsenic Compound Realgar Effectively Targets Myeloma Stem-Like Side Population

Myeloma Patient-Derived Mesenchymal Stem Cells Grown In 3-D Culture Induce Primary Myeloma Cell Proliferation and Resistance To Therapy

Mouse Versus Human Extrinsic Cues Dictate Transformation Potential In BCR-ABL/BMI1-Induced Leukemia In Humanized Xenograft Models

CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients

Daratumumab, a Novel Human CD38 Monoclonal Antibody for Treatment of Multiple Myeloma, Prevents Intra-Medullary Spreading of Patient Derived Multiple Myeloma Cells Growing in a Humanized Mouse Model

Tumor Cell-Dependent Differences in Stroma-Induced Changes to Bortezomib Sensitivity.

Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model

Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents

Phagocytosis Is A Mechanism of Action for Daratumumab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only